目的观察和分析化疗间期联合序贯应用厄洛替尼治疗晚期非小细胞肺癌(NSCIC)的疗效。方法选取晚期NSCIC患者45例作为研究对象,对于初治患者应用吉西他滨联合铂类进行化疗,对于复治患者应用多西他赛或培美曲塞进行化疗,在化疗间期应用厄洛替尼进行序贯治疗。对患者的近期疗效和毒副反应进行评价和比较。结果初治患者和复治患者的临床有效率分别为27.6%和18.8%,初治患者和复治患者的各项近期疗效结果及临床有效率的差异均无显著性(P0.05),而初治患者的临床控制率显著高于复治患者(P0.05);具有吸烟史患者的临床有效率显著低于无吸烟史的患者(P0.05),年龄≥65岁的初治患者的临床有效率显著高于年龄65的初治患者(P0.05),Ⅲb期的初治患者的临床有效率显著高于Ⅳ期的初治患者(P0.05),病理类型为腺癌的复治患者的临床有效率显著高于病理类型为非腺癌的复治患者(P0.05);患者的主要副反应为皮疹、恶心、腹泻、呕吐、食欲减退等方面。结论化疗间期联合序贯应用厄洛替尼治疗晚期NSCLC的临床有效率并不高,吸烟史、年龄、肿瘤分期、病理类型都可能对其疗效产生影响,这种疗法在控制初治患者病情进展方面的效果较显著,且副反应较轻,患者的可耐受度较高。

Objective To observe and analyze the curative effects of the combined sequential application of erlotinib between the chemotherapy periods in the treatment of the patients with ad-vanced non small cell lung cancer (NSCLC).Methods 45 patients with advanced NSCLC were se-lected as the research objects.The patients of the initial treatment were treated with gemcitabine combined with platinum for chemotherapy and the patients of retreatment were treated with doc-etaxel or pemetrexed for chemotherapy.Between the chemotherapy periods,the sequential erlotinib therapy was applied to all the patients.The short-term curative effects and the adverse reactions were evaluated and compared.Results The clinical efficiency of the initial treatment patients and the retreatment patients were 27.6% and 18.8% respectively.There were no significant differences of short-term curative effects and the clinical efficiency between the initial treatment patients and the retreatment patients (P >0.05),while the c

探讨外周血CD4+CD25+CD127low调节性T细胞(regulatory T cells,Tregs)在多发性骨髓瘤(multiple myeloma,MM)治疗中的作用。方法:采用流式细胞术检测30例初治、27例完全缓解(CR)MM患者以及25例健康成年人外周血CD4+T细胞、Tregs数量,并检测Tregs表面功能分子CTLA-4及其凋亡相关蛋白CD95、bcl-2、Caspase3的表达,分析其与临床特点及疗效的关系。结果:初治组CD4+T细胞占外周血单个核细胞的比例低于对照组(P0.05),Ⅲ期初治患者CD4+T细胞明显低于Ⅰ、Ⅱ期患者(P0.05);初治MM组Tregs占CD4+T细胞比例显著高于CR组和正常对照组(P0.05),初治Ⅲ期患者Tregs占CD4+T细胞比例明显高于初治Ⅰ、Ⅱ期患者(P0.05)。初治组、CR组和正常对照组Tregs的表面CD95表达无统计学差异(P0.05),初治组CTLA-4表达高于CR组(P0.05)和对照组(P0.01),CR患者CTLA-4高于对照组(P0.05),初治组Tregs胞浆内bcl-2水平高于CR组(P0.05)和对照组(P0.01),CR组高于对照组(P0.05),初治组和CR组Tregs胞内Caspase3的水平低于对照组(P0.05)。初治组Tregs占CD4+比例与骨髓瘤数量呈正相关(P0.05),且Tregs比例与治疗前后浆细胞下降值成反比(r=0.735,P0.05)。结论:MM患者外周血Tregs水平升高,与瘤细胞负荷及疾病的分期呈正相关,与疗效呈负相关;Tregs水平增高与其抗凋亡能力增强有关。

To investigate the role of CD4+, CD25+, and CD127low regulatory T cells (Tregs) in multiple myeloma (MM). Methods:Levels of CD4+T cells and Tregs, as well as expression of CTLA-4 and apoptosis-related proteins, such as CD95, bcl-2, and Caspase3 of Tregs in peripheral blood of 30 patients with newly diagnosed cases, 27 patients under of complete remission (CR) from multiple myeloma patients, and 25 healthy adults were analyzed by flow cytometry. Results:The percentage of CD4+T cells in the untreated group was significantly lower than that of the control group (P<0.05). The percentage of Tregs in CD4+T cells in the untreated group was significantly higher than that of the CR group and control group (P<0.05), which in ISSⅢpatients of the untreated group was significantly higher than that in I/II(P<0.05). No significant difference of CD95 expression in Tregs was observed among the three groups. The expression of CTLA-4 in Tregs from the untreated group was significantly higher t

目的：探讨VTLP方案治疗初治成人急性淋巴细胞白血病的临床疗效。方法98例成人初治急性淋巴细胞白血病患者分为2组，每组49例，VDLP方案组行VDLP方案诱导化疗，VTLP方案组行VTLP方案诱导化疗。结果2组化疗后的完全缓解率比较差异无统计学意义（P>0.05）；VTLP方案组骨髓抑制程度、继发感染率及复发率均低于VDLP方案组（ P<0.05）。结论与VTLP方案治疗初治成人急性淋巴细胞白血病高效低毒，可作为成人初治急性淋巴细胞白血病的诱导化疗方案。

Objective ToinvestigatetheclinicaleffectsofVTLPregimeninthetreatmentofnewlydiagnoseda-dultacutelymphoblasticleukemia.Methods Ninety-eightcasesofnewlydiagnosedadultacutelymphoblasticleu-kemia were randomly divided into two groups,49 cases of the VDLP regimen group received VDLP regimen induc-tion chemotherapy,and 49 cases of the VTLP regimen group received VTLP regimen induction chemotherapy. Re-sults Therewasnostatisticaldifferenceinthecompleteremissionratebetweenthetwogroups(P>0.05).The bone marrow suppression degree,secondary infection rate and recurrence rate in the VTLP regimen group were low-erthanthoseintheVDLPregimengroup(P<0.01).Conclusion VTLPregimencanbeusedasaprimarytreat-ment of adult acute lymphoblastic leukemia.

目的：观察肺结核患者血清 caspase-3活性。方法选取广西医科大学第一附属医院感染科2010年12月住院肺结核患者38例，其中肺结核初治结核杆菌痰涂片阳性13例、肺结核初治结核杆菌痰涂片阴性15例、肺结核复治耐药10例，于入院次日采集外周静脉血，同时选取健康体检者22例为对照组采用分光光度法检测肺结核患者血清 caspase-3酶活力单位，即 caspase-3催化产生的4-硝基苯胺（pNA）的吸光度（A）。结果肺结核初治结核杆菌痰涂片阳性组、肺结核初治结核杆菌痰涂片阴性组、肺结核复治耐药组、正常对照组血清 caspase-3酶活力单位分别为37.15±5.06，50.38±6.29，45.32±3.32和23.89±2.29。各组之间 caspase-3活性差异具有统计学意义（F＝10.68，P＜0.01）。与正常对照组相比，肺结核初治涂阳组（q＝3.51，P＝0.016）、肺结核初治涂阴组（q＝7.5，P＜0.001）、肺结核复治耐药组（q＝5.34，P＝0.001） caspase-3活性差异具有统计学意义。肺结核患者各亚组（耐药组、涂阳组、涂阴组）之间 caspase-3活性差异无统计学意义（P＞0.05）。各组之间性别构成比[χ2＝0.38（DL＝3），P＝0.94]差异无统计学意义；各组之间年龄差异亦无统计学意义（F＝0.82，P＝0.49）。结论 caspase-

Objective To explore serum caspase-3 activity in pulmonary tuberculosis patients.Methods 38 tuberculosis pa-tients in Infectious Disease Department in the First Affiliated Hospital of Guangxi Medical University were recruited and the peripheral venous blood was collected in December,2010.Among them,sputum smear-positive patients which were first treated were 13,sputum smear-negative patients which were first treated were 15,10 cases were drug resistance.In addition, 22 unrelated healthy individuals from a routine health survey were enrolled as controls.Spectrophotometry was used to de-tect serum caspase-3 activity in tuberculosis patients,which was absorbancy-A of 4-nitroaniline generated by caspase-3.Re-sults The activity of caspase-3 in sputum smear-positive patients,sputum smear-negative patients,drug resistance patients, and healthy controls were 37.15±5.06,50.38±6.29,45.32±3.32 and 23.89±2.29,respectively.The caspase-3 activity was significantly different from each o

目的 分析汕头市住院耐多药肺结核患者结核分枝杆菌对二线抗结核药物的耐药情况,为制定治疗方案提供依据.方法 分析2010年8月至2012年7月135例住院耐多药肺结核患者结核分枝杆菌对Am、Lfx和Pto的药物敏感性试验结果,观察初治组和复治组对二线抗结核药物的耐药率.结果 初治组耐Lfx 10.0％、耐Am 10.0％、耐Pto 6.7％,复治组耐Lfx 23.8％、耐Am 17.1％、耐Pto 4.8％;初治组未发现广泛耐药患者,复治组中广泛耐药患者13例(12.4％).结论 对于耐多药肺结核患者,进行二线抗结核药物敏感试验,有利于耐多药肺结核个体化方案的制定.

Objective To analyze resistant situation to second-line anti-TB drugs of mycobacterium tuberculosis among inpatients with MDR-TB in the Third People''s Hospital of Shantou,and provide the evidence for making the treatment regimens.Methods The analysis was conducted on drug susceptibility testing to Am,Lfx and Pto of mycobacterium tuberculosis among 135 inpatients with MDR-TB from Aug 1 st,2010 to Jul 31st,2012.The second-line drug resistance rate of new treatment group and re-treatment group were observed.Results The secondline drug resistance rate of Lfx,Am and Pro in new treatment group were 10.0％,10.0％ and 6.7％ respectively,23.8％,17.1％ and 4.8％ respectively in re-treatment group.There were no XDR-TB patients in new treatment group,and 13 XDR-TB patients (accounting for 12.4％) were found in re-treatment group.Conclusion The second-line anti-TB drug susceptibility testing will help us to make the individual treatment regimens for the MDR-TB patients.